Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research

van der Heijde, Désirée; Gladman, Dafna D.; Kavanaugh, Arthur; Mease, Philip J.

doi:10.1186/s13075-020-2103-8

Arthritis Research & Therapy

Table 2 Assessment of radiographic progression in psoriatic arthritis trials

From: Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research

Study	Scoring method	Radiographic assessment time point, week	Mean change in radiographic score at week 24		Proportion of patients with no progression (mean change ≤ 0.5) at week 24, %
Study	Scoring method	Radiographic assessment time point, week	Placebo	Active treatment	Placebo	Active treatment
Etanercept vs placebo (phase 3) [15, 16]	Sharp	24 and 48	1.0^a	− 0.03^a	8.6^a,b	33.8^a,b
ADEPT (adalimumab vs placebo) [17, 18]	Sharp	24	1.0	− 0.2	71.1	91.0
IMPACT (infliximab vs placebo) [19]	SvdH	50	− 1.95 (PBO/infliximab)^c	− 1.52^c	84.8 (PBO/infliximab)^c	83.8^c
IMPACT 2 (infliximab vs placebo) [20]	SvdH	24 and 54	0.82	− 0.70	78.0	90.0
GO-REVEAL (golimumab vs placebo) [21]	SvdH	24 and 52	0.27	− 0.09	62.7^b	77.7^b
GO-VIBRANT (golimumab vs placebo) [22]	SvdH	24	2.0	− 0.4	43.0^b	71.7^b
RAPID-PsA (certolizumab pegol) [23, 24]	SvdH	12 and 24	0.28	0.06 (200 mg Q2W + 400 mg Q4W)	80.1	93.5 (200 mg Q2W); 90.4 (400 mg Q4W)
PSUMMIT-1 and -2 (ustekinumab vs placebo) [25]	SvdH	24 and 52	1.0	0.4	59.8^b	66.5^b
FUTURE 1 (secukinumab vs placebo) [26]	SvdH	16 or 24 and 52	0.57	0.08 (pooled secukinumab group)	75.7	82.3 (IV → 150 mg); 92.3 (IV → 75 mg)
FUTURE 5 (secukinumab vs placebo) [27]	SvdH	24	0.5	0.08 (300 mg + LD); 0.17 (150 mg + LD); − 0.09 (150 mg − LD)	73.6	88.0^.(300 mg + LD); 79.8 (150 mg + LD); 83.8 (150 mg − LD)
SPIRIT-P1 (ixekizumab vs placebo vs adalimumab) [28]	SvdH	24 and 52	0.27 (PBO/IXEQ4W)^d; 0.41 (PBO/IXEQ2W)^d	0.54 (IXEQ4W/IXEQ4W)^d; 0.09 (IXEQ2W/IXEQ2W)^d; 0.32 (ADA/IXEQ4W)^d; − 0.03 (ADA/IXEQ2W)^d	94.1 (PBO/IXEQ4W)^d; 65.7 (PBO/IXEQ2W)^d	88.9 (IXEQ4W/IXEQ4W)^d; 90.4 (IXEQ2W/IXEQ2W)^d; 87.5 (ADA/IXEQ4W)^d; 91.4 (ADA/IXEQ2W)^d
ASTRAEA (abatacept vs placebo) [29]	SvdH	24 and 52	0.35	0.30	32.7^b	42.7^b
OPAL Broaden (tofacitinib vs adalimumab vs placebo) [30]	SvdH	12 months	Not reported by treatment arm. Range of change from baseline, − 0.07 to 0.09^a		95.8 (PBO/TOFA 5 mg)^a; 91.1 (PBO/TOFA 10 mg)^a	95.9 (TOFA 5 mg)^a; 94.9 (TOFA 10 mg)^a; 97.9 (ADA)^a
SEAM-PsA (methotrexate vs etanercept vs combination) [31]	SvdH	24 and 48	–	0.08 (MTX)^e; − 0.04 (ETN)^e; − 0.01 (MTX + ETN)^e	–	89.4 (MTX)^b,e; 94.7 (ETN)^b,e; 94.7 (MTX + ETN)^b,e

ADA adalimumab, ETN etanercept, IXE ixekizumab, LD loading dose, MTX methotrexate, PBO placebo, PsA psoriatic arthritis, Q2W every 2 weeks, Q4W every 4 weeks, SvdH modified Sharp-van der Heijde score for PsA, TOFA tofacitinib
^aMean change from baseline at 12 months
^bNo progression was defined as a mean change of ≤ 0 from baseline
^cMean change from baseline at week 50
^dMean change from baseline at week 52
^eMean change from baseline at week 48

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com